Listen
PREVENAR 20 (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)) - Pneumococcal infections
Reason for request
Summary of opinion
Favourable opinion for maintenance of reimbursement in active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥ 18 years of age, in accordance with the HAS vaccination recommendations of 19 December 2024.
Clinical Benefit
| Substantial |
The clinical benefit of PREVENAR 20 (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)) remains substantial in the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥ 18 years of age, in accordance with the current HAS recommendations issued on 19 December 2024. |
Clinical Added Value
| no clinical added value |
Updating of the vaccine strategy in accordance with the current HAS recommendations of 19 December 2024 does not modify the clinical added value level (CAV V according to the opinion of 18/10/2023) in the active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥ 18 years of age. |
